Best Lynch-Style Stocks in Biotechnology for 2026
Growth at a reasonable price (GARP): strong growth with reasonable valuations.
Biotechnology spans the cash-generative commercial-stage companies and the pre-revenue clinical-stage cohort. Composite scoring is harsh on cash-burning names via the Health pillar (runway, cash to market cap); commercial-stage biotechs surface through the Quality pillar (gross margin, ROIC) and Valuation pillar.
Data as of (updated daily)
Top 20 Biotechnology stocks by composite score
| # | Ticker | Name | Composite |
|---|---|---|---|
| 1 | 002653.SHE | Xizang Haisco Pharmaceutical Group Co Ltd | 70.9 |
| 2 | 005690.KO | Pharmicell | 60.6 |
| 3 | 068270.KO | Celltrion Inc | 64.2 |
| 4 | INCY.US | Incyte Corporation | 82.6 |
| 5 | PLX.US | Protalix Biotherapeutics Inc | 69.0 |
| 6 | PRTA.US | Prothena Corporation plc | 67.8 |
| 7 | WVE.US | Wave Life Sciences Ltd | 58.2 |
| 8 | DXB.AU | Dimerix Ltd | 58.8 |
| 9 | PHM.MC | Pharma Mar S.A. | 62.8 |
| 10 | INSM.US | Insmed Inc | 51.1 |
| 11 | MSB.AU | Mesoblast Ltd | 59.5 |
| 12 | CYTK.US | Cytokinetics Inc | 50.0 |
| 13 | 2269.HK | WuXi Biologics | 61.4 |
| 14 | AUPH.US | Aurinia Pharmaceuticals Inc | 69.2 |
| 15 | ICCC.US | ImmuCell Corporation | 61.7 |
| 16 | MESO.US | Mesoblast Ltd | 53.9 |
| 17 | LPCN.US | Lipocine Inc | 59.0 |
| 18 | IMM.AU | Immutep Ltd | 52.8 |
| 19 | VCEL.US | Vericel Corp Ord | 57.0 |
| 20 | RIGL.US | Rigel Pharmaceuticals Inc | 68.7 |
Customise the lynch-style stocks + biotechnology screen
The full screener applies both filters and lets you stack 30+ more on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Lynch-Style Stocks in other industries
Other strategies in Biotechnology
Browse the hub pages
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by composite score within the Biotechnology industry; use the screener for the full ranked list.